Category: Pharma, Life Sciences & Med Tech Players
-
Pharma giant Takeda ordered to pay over $884 million in damages in Amitiza class action suit: patent litigation settlement was anticompetitive, jury finds
Takeda has said it already plans to “vigorously” appeal the decision, which found its 2014 deal with competitor Par Pharmaceutical to drop its challenge to its AMITIZA patents and delay its generic entry by seven years, anticompetitive.
-
Actelion falls foul of disclosure-dedication rule, prosecution estoppel in Federal Circuit challenge to Mylan’s hypertension generic
The Federal Circuit agreed that there was neither literal infringement, nor infringement under the doctrine of equivalents.
-
CureVac expands Spikevax patent fight to UPC with new action against Moderna in Hague LD
In a significant patent battle for mRNA vaccines, CureVac has now joined others in suing in the UPC, taking the dispute with Moderna, which started in Delaware, to the Hague LD.
-
District judge opens door to rare “reverse doctrine of equivalents” defense in medical device dispute
The judge’s order came amid long-running litigation between Maquet and Abiomed in the United States District Court for the District of Massachusetts over intravascular blood pump technologies.
-
Federal Circuit analysis would create “substantial disincentive” to generic entry, USDOJ tells Supreme Court in Hikma v. Amarin
The key arguments centred on whether it was plausible that Hikma’s marketing amounted to inducement to infringe.
-
Merz wins UPC appeal as CoA overturns Paris LD denial and grants PI against Viatris generic in France
The UPC CoA has reversed the Paris LD’s refusal of interim relief and granted Merz a preliminary injunction against Viatris Santé’s fampridine generic in France.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.
-
CureVac sues Moderna in Delaware over Spikevax patents, seeking treble damages but no injunction
CureVac sues Moderna for treble damages but not an injunction over 10 patents related to Spikevax. The case adds to broader post-COVID mRNA patent battles.
-
Human lives at stake: Munich court warns against chilling effect of excessive prior art eligibility as rivaroxaban dispute heads into final round
All other Munich landmark rulings related to access to injunctive relief, be it about SEPs, the invalidity defense to PIs, or anti-antisuit relief in different forms. The latest one is about patients more so than patents.
-
Federal Circuit revives Teva’s $177M (potentially $530M) damages verdict against Eli Lilly over Emgality headache drug
A $177M jury verdict, potentially tripled for willfulness, has been reinstated, and the standards for written description and enablement for genus-related patents have been clarified.